Neurocrine’s Ingrezza — the first treatment for the nervous system disorder tardive dyskinesia — continues to rake in revenue.

In the second quarter, the San Diego company reported Ingrezza sales of $96.9 million. Released May 2017, the drug’s increased adoption has significantly improved the company’s balance sheet.

For instance, in the second quarter, the company listed a net loss of $5.9 million, compared to a loss of $60 million in the prior year period.

Neurocrine recently received another good piece of news: Orilissa, developed in collaboration with AbbVie, won U.S. Food and Drug Administration approval. With that, Neurocrine will receive a $40 million payment, which will be recorded as third quarter revenue.

Neurocrine said that it had $841.3 million in assets, including cash, investments and about $800 million in receivables, as of June 30.